

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:       Guy VAN DEN MOOTER et al.   Confirmation No.:   2958  
Serial No.:       10/595,119                           Art Unit:            1797  
371(c) Date:     February 23, 2006               Examiner:           D.A. Reifsnyder  
Customer No.:   21559  
Title:            PARTICLE SIZE REDUCTION OF BIOACTIVE COMPOUNDS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. §§ 1.321 and 3.73(b)

Pursuant to 37 C.F.R. § 1.321(b), K.U.Leuven Research & Development, the assignee of the entire right, title, and interest in the above-captioned application, seeks to disclaim the terminal portion of the term of the patent to be granted on the application. This terminal disclaimer is binding on the grantee and its successors or assigns.

Pursuant to 37 C.F.R. § 1.321(b)(1), this terminal disclaimer is signed by an attorney of record.

Pursuant to 37 C.F.R. § 1.321(b)(2), K.U.Leuven Research & Development hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the application subsequent to the expiration date of U.S. Patent No. 7,384,560. K.U.Leuven Research & Development does not disclaim any terminal part of any patent granted on the application prior to the expiration date of the full statutory term of U.S. Patent No. 7,384,560 in the event that it later: expires for failure to pay a maintenance fee,

is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above.

Pursuant to 37 C.F.R. § 1.321(b)(3) and § 3.73(b), the undersigned attorney of record certifies that K.U.Leuven Research & Development, a university, is the assignee of the entire right, title, and interest in the application by virtue of:

An assignment from the inventors of the application. The assignment was Recorded in the Patent and Trademark Office at Reel/Frame 017384/0307 on March 29, 2006. A copy of the assignment is enclosed.

The undersigned attorney of record has reviewed all the documents in the chain of title of the application and to the best of the undersigned's knowledge and belief, title is in the name of K.U.Leuven Research & Development.

Pursuant to 37 C.F.R. § 1.321(b)(4), transmitted herewith is payment of the fee set forth in 37 C.F.R. § 1.20(d).

Further, pursuant to 37 C.F.R. § 1.321(c)(3), this terminal disclaimer is being filed to overcome a double patenting rejection in the application. Any patent granted on the application or any resulting patent subject to reexamination proceedings shall be enforceable only for and during such period that the patent is commonly owned with the application or patent that formed the basis for the rejection.

If there are any additional charges or any credits, please apply them to Deposit

Account Number 03-2095.

Respectfully submitted,

Date: 8/7/2009

  
\_\_\_\_\_  
James D. DeCamp  
Reg. No. 43,580

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

## ASSIGNMENT

For valuable consideration, we,

Full Name of Assignor	City	State (and Country if not USA)
Guy VAN DEN MOOTER	Pellenberg	BELGIUM
Johan MARTENS	Huidenberg	BELGIUM
Jan NUYENS	Vosselaar	BELGIUM

hereby assign to

Full Name of Assignee	State of Incorporation	Business Address
K.U. Leuven Research & Development	Belgium	Groot Begijnhof 58-59 3000 Leuven Belgium

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more applications for United States Patent signed by us, identified as:

Title of Application	Filing Date	Serial Number
PARTICLE SIZE REDUCTION OF BIOACTIVE COMPOUNDS	February 23, 2006	10/595,119


and we authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting above the filing date and serial number of said application when known; this assignment includes said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment

Filing Date: February 23, 2006  
U.S. Patent Application Serial No. 10/595,119

*[Signature]*

March 14th 2006  
Date

Date \_\_\_\_\_



March 8th, 2006

---

Date

Date \_\_\_\_\_

an NUYENS

**Date**

March 8th, 2006